Recognition and Management of Metabolic Epilepsies
This video presents a clinically grounded overview of recent advances in neurogenetics and precision-based therapies for severe childhood-onset neurological disorders, including Dravet syndrome and related epileptic encephalopathies
Clinical Scorecard: Recognition and Management of Metabolic Epilepsies
At a Glance
Category Detail
Condition Severe childhood-onset neurological disorders including Dravet syndrome and related epileptic encephalopathies Key Mechanisms Single-gene mutations disrupting neuronal signaling, network stability, and neurodevelopment Target Population Pediatric patients with genetic epileptic encephalopathies Care Setting Specialized pediatric neurology and neurogenetics clinics
Key Highlights
Disease pathophysiology is increasingly understood at genetic and cellular levels, informing novel therapies. Traditional antiseizure and supportive therapies have limitations; disease-modifying approaches are needed. Emerging therapies include gene replacement, gene modulation, and RNA-based strategies with ongoing clinical trials. Guideline-Based Recommendations
Diagnosis
Utilize genetic testing to identify single-gene mutations causing epileptic encephalopathies. Assess multisystem involvement to understand complex seizure phenotypes. Management
Implement precision-based therapies targeting underlying genetic mechanisms rather than symptom control alone. Consider emerging genetic and molecular therapies such as gene replacement and RNA-based strategies. Monitoring & Follow-up
Conduct rigorous clinical research with standardized outcome measures. Perform long-term follow-up to assess safety and efficacy of novel therapies. Risks
Be aware of delivery challenges of therapies within the central nervous system. Monitor for safety considerations related to gene and molecular therapies. Patient & Prescribing Data
Children with severe genetic epileptic encephalopathies
Early clinical trial outcomes show promise but require careful evaluation of safety and delivery methods.
Clinical Best Practices
Incorporate genetic and molecular diagnostics early in the evaluation process. Adopt a multidisciplinary approach including neurology, genetics, and clinical research teams. Prioritize disease-modifying treatments over symptomatic antiseizure medications when appropriate. Ensure standardized outcome measures and long-term monitoring in clinical practice. References
